Update of drug-resistant tuberculosis treatment guidelines: A turning point

•A guideline update regarding drug-resistant tuberculosis (DR-TB) treatment has been recently published by World Health Organization.•6-month bedaquiline, pretomanid, linezolid (600 mg), and moxifloxacin (BPaLM) is recommended rather than 9-month or longer regimens in multi DR/rifampicin-resistant T...

Celý popis

Podrobná bibliografia

Vydané v:	International journal of infectious diseases Ročník 130; s. S12 - S15
Hlavní autori:	Vanino, Elisa, Granozzi, Bianca, Akkerman, Onno W., Munoz-Torrico, Marcela, Palmieri, Fabrizio, Seaworth, Barbara, Tiberi, Simon, Tadolini, Marina
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Canada Elsevier Ltd 01.05.2023 Elsevier
Predmet:	Antitubercular Agents - pharmacology DR-TB treatment guidelines Extensively Drug-Resistant Tuberculosis - drug therapy Humans Longer regimens MDR/RR-TB Rifampin - pharmacology Shorter regimen Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Pulmonary - drug therapy Longer regimens Shorter regimen MDR/RR-TB DR-TB treatment guidelines
ISSN:	1201-9712, 1878-3511, 1878-3511
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!